20/09/2000
The Cambridge-based biotech firm has decided against selling itself, and has instead opted for a strategic alliance with US pharmaceutical giant Baxter. This tie-up also involves a £27.8m investment by Baxter in Peptide, which is planning to change its name to Acambis. A third major development is the news that OraVax, its US subsidiary, has been awarded a $343m contract from the US government to develop a smallpox vaccine. The contract, which is set to run for 20 years, is to allow the US government to build up a stockpile of the vaccine to counter a bioterrorist attack. Separately, the Arilvax yellow fever vaccine successfully passed Phase III trials and is set to be marketed by Baxter. The balance sheet is still strong with over £15.7m of cash. Overall, Peptide/Acambis is in rude health. A strong buy.
| Market cap: | £75.5m |
| PE Average: | n/a |
| PE Forecast: | n/a |
| PE Historic: | n/a |
| Share price: | 99.5p |
| LSE | 0pm |
p
|
p
|
|
| Other company articles: |
| 21/01/2008 |
| 01/04/2003 |
| 01/05/2002 |
| 02/04/2002 |
| 29/11/2001 |
Agency Commercial Mortgage
Looking for Agency Commercial Mortgage? Search over 15,000 sites with one click. Your source for everything under the sun.
Agency Commercial Mortgage - Check Out I Found It
All the top companies and links for agency commercial mortgage under one roof at I-Found-It.
